Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice

References

• Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12:237 - 51; http://dx.doi.org/10.1038/nrc3237; PMID: 22437869
   PubMed Web of Science ®Google Scholar
• Shapira S, Lisiansky V, Arber N, Kraus S. Targeted immunotherapy for colorectal cancer: monoclonal antibodies and immunotoxins. Expert Opin Investig Drugs 2010; 19:Suppl 1 S67 - 77; http://dx.doi.org/10.1517/13543781003737668; PMID: 20374033
   PubMed Web of Science ®Google Scholar
• Croci DO, Zacarías Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother 2007; 56:1687 - 700; http://dx.doi.org/10.1007/s00262-007-0343-y; PMID: 17571260
   PubMed Web of Science ®Google Scholar
• Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5:263 - 74; http://dx.doi.org/10.1038/nrc1586; PMID: 15776005
   PubMed Web of Science ®Google Scholar
• Melero I, Mazzolini G, Narvaiza I, Qian C, Chen L, Prieto J. IL-12 gene therapy for cancer: in synergy with other immunotherapies. Trends Immunol 2001; 22:113 - 5; http://dx.doi.org/10.1016/S1471-4906(00)01824-X; PMID: 11286714
   PubMed Web of Science ®Google Scholar
• Malvicini M, Rizzo M, Alaniz L, Piñero F, García M, Atorrasagasti C, et al. A novel synergistic combination of cyclophosphamide and gene transfer of interleukin-12 eradicates colorectal carcinoma in mice. Clin Cancer Res 2009; 15:7256 - 65; http://dx.doi.org/10.1158/1078-0432.CCR-09-1861; PMID: 19920110
   PubMed Web of Science ®Google Scholar
• Malvicini M, Ingolotti M, Piccioni F, Garcia M, Bayo J, Atorrasagasti C, et al. Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12. Mol Oncol 2011; 5:242 - 55; http://dx.doi.org/10.1016/j.molonc.2011.03.007; PMID: 21515097
   PubMed Web of Science ®Google Scholar
• Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4:423 - 36; http://dx.doi.org/10.1038/nrc1369; PMID: 15170445
   PubMed Web of Science ®Google Scholar
• Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol 2011; 33:369 - 83; http://dx.doi.org/10.1007/s00281-011-0245-0; PMID: 21611872
   PubMed Web of Science ®Google Scholar
• Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 2000; 60:2190 - 6; PMID: 10786683
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. Cancer J 2010; 16:348 - 53; http://dx.doi.org/10.1097/PPO.0b013e3181eb3358; PMID: 20693846
   PubMed Web of Science ®Google Scholar
• Shurin GV, Tourkova IL, Kaneno R, Shurin MR. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol 2009; 183:137 - 44; http://dx.doi.org/10.4049/jimmunol.0900734; PMID: 19535620
   PubMed Web of Science ®Google Scholar
• Matar P, Rozados VR, Gervasoni SI, Scharovsky GO. Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother 2002; 50:588 - 96; http://dx.doi.org/10.1007/s00262-001-0237-3; PMID: 11807622
   PubMed Web of Science ®Google Scholar
• Taieb J, Chaput N, Schartz N, Roux S, Novault S, Ménard C, et al. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol 2006; 176:2722 - 9; PMID: 16493027
   PubMed Web of Science ®Google Scholar
• Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 2011; 29:4491 - 7; http://dx.doi.org/10.1200/JCO.2011.36.7045; PMID: 22042958
   PubMed Web of Science ®Google Scholar
• Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother 2012; 61:353 - 62; http://dx.doi.org/10.1007/s00262-011-1106-3; PMID: 21915801
   PubMed Web of Science ®Google Scholar
• Cerullo V, Diaconu I, Kangasniemi L, Rajecki M, Escutenaire S, Koski A, et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther 2011; 19:1737 - 46; http://dx.doi.org/10.1038/mt.2011.113; PMID: 21673660
   PubMed Web of Science ®Google Scholar
• Rozados VR, Mainetti LE, Rico MJ, Zacarías Fluck MF, Matar P, Scharovsky OG. The immune response and the therapeutic effect of metronomic chemotherapy with cyclophosphamide. Oncol Res 2010; 18:601 - 5; http://dx.doi.org/10.3727/096504010X12777678141662; PMID: 20939436
   PubMed Web of Science ®Google Scholar
• Penel N, Adenis A, Bocci G. Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?. Crit Rev Oncol Hematol 2012; 82:40 - 50; http://dx.doi.org/10.1016/j.critrevonc.2011.04.009; PMID: 21641231
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010; 127:759 - 67; PMID: 20518016
   PubMed Web of Science ®Google Scholar
• Barnett BG, Rüter J, Kryczek I, Brumlik MJ, Cheng PJ, Daniel BJ, et al. Regulatory T cells: a new frontier in cancer immunotherapy. Adv Exp Med Biol 2008; 622:255 - 60; http://dx.doi.org/10.1007/978-0-387-68969-2_20; PMID: 18546633
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 2007; 13:4345 - 54; http://dx.doi.org/10.1158/1078-0432.CCR-07-0472; PMID: 17671115
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Gooding W, Johnson JT, Whiteside TL. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007; 13:6301 - 11; http://dx.doi.org/10.1158/1078-0432.CCR-07-1403; PMID: 17975141
   PubMed Web of Science ®Google Scholar
• Yaqub S, Henjum K, Mahic M, Jahnsen FL, Aandahl EM, Bjørnbeth BA, et al. Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol Immunother 2008; 57:813 - 21; http://dx.doi.org/10.1007/s00262-007-0417-x; PMID: 17962941
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56:641 - 8; http://dx.doi.org/10.1007/s00262-006-0225-8; PMID: 16960692
   PubMed Web of Science ®Google Scholar
• Wittke F, Hoffmann R, Buer J, Dallmann I, Oevermann K, Sel S, et al. Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. Br J Cancer 1999; 79:1182 - 4; http://dx.doi.org/10.1038/sj.bjc.6690189; PMID: 10098756
   PubMed Web of Science ®Google Scholar
• Fortis C, Foppoli M, Gianotti L, Galli L, Citterio G, Consogno G, et al. Increased interleukin-10 serum levels in patients with solid tumours. Cancer Lett 1996; 104:1 - 5; http://dx.doi.org/10.1016/0304-3835(96)04213-9; PMID: 8640735
   PubMed Web of Science ®Google Scholar
• Matar P, Rozados VR, Gervasoni SI, Scharovsky OG. Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response. Int Immunopharmacol 2001; 1:307 - 19; http://dx.doi.org/10.1016/S1567-5769(00)00028-X; PMID: 11360931
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162 - 74; http://dx.doi.org/10.1038/nri2506; PMID: 19197294
   PubMed Web of Science ®Google Scholar
• Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010; 70:3052 - 61; http://dx.doi.org/10.1158/0008-5472.CAN-09-3690; PMID: 20388795
   PubMed Web of Science ®Google Scholar
• Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11:6713 - 21; http://dx.doi.org/10.1158/1078-0432.CCR-05-0883; PMID: 16166452
   PubMed Web of Science ®Google Scholar
• Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000; 6:1755 - 66; PMID: 10815894
   PubMed Web of Science ®Google Scholar
• Salvadori S, Martinelli G, Zier K. Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol 2000; 164:2214 - 20; PMID: 10657677
   PubMed Web of Science ®Google Scholar
• Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002; 2:151 - 61; http://dx.doi.org/10.1038/nri746; PMID: 11913066
   PubMed Web of Science ®Google Scholar
• Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009; 9:353 - 63; http://dx.doi.org/10.1038/nri2545; PMID: 19365408
   PubMed Web of Science ®Google Scholar
• Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res 2011; 71:768 - 78; http://dx.doi.org/10.1158/0008-5472.CAN-10-2788; PMID: 21156650
   PubMed Web of Science ®Google Scholar
• van den Engel NK, Rüttinger D, Rusan M, Kammerer R, Zimmermann W, Hatz RA, et al. Combination immunotherapy and active-specific tumor cell vaccination augments anti-cancer immunity in a mouse model of gastric cancer. J Transl Med 2011; 9:140; http://dx.doi.org/10.1186/1479-5876-9-140; PMID: 21859450
   PubMed Web of Science ®Google Scholar
• Mazzolini G, Qian C, Xie X, Sun Y, Lasarte JJ, Drozdzik M, et al. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. Cancer Gene Ther 1999; 6:514 - 22; http://dx.doi.org/10.1038/sj.cgt.7700072; PMID: 10608348
   PubMed Web of Science ®Google Scholar
• Melero I, Gabari I, Tirapu I, Arina A, Mazzolini G, Baixeras E, et al. Anti-ICAM-2 monoclonal antibody synergizes with intratumor gene transfer of interleukin-12 inhibiting activation-induced T-cell death. Clin Cancer Res 2003; 9:3546 - 54; PMID: 14506140
   PubMed Web of Science ®Google Scholar
• Alaniz L, Rizzo M, Malvicini M, Jaunarena J, Avella D, Atorrasagasti C, et al. Low molecular weight hyaluronan inhibits colorectal carcinoma growth by decreasing tumor cell proliferation and stimulating immune response. Cancer Lett 2009; 278:9 - 16; http://dx.doi.org/10.1016/j.canlet.2008.12.029; PMID: 19185418
   PubMed Web of Science ®Google Scholar